Notably, this appeared to be driven largely by an 80% reduction in breast cancer related deaths in BRCA1 carriers, whereas there was no statistically significant effect of MRI on reducing mortality in those with BRCA2 pathogenic variants. The gene discussed is BRCA1; the disease is breast carcinoma.